Filings & corporate actions
40 results filed
CSVNext results · Q2 FY27
Expected 4 Nov 2026 – 11 Nov 2026
Estimate: filed 35–42 days after quarter end, last 5 times
2026
- 6 AugresultsResults · Q1 FY27 · standalone+1.0%NSE
- 8 JulshareholdingShareholding · 30 Jun 2026-7.1%NSE
- 21 MayresultsResults · Q4 FY26 · standalone+5.0%NSE
- 13 AprshareholdingShareholding · 31 Mar 20260.0%NSE
- 9 FebresultsResults · Q3 FY26 · standalone-1.4%NSE
- 5 JanshareholdingShareholding · 31 Dec 2025-2.0%NSE
Reaction to results · all yearsrose on day 0 in 9 of 75 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 6 Aug 2026 | +1.0% | +0.2% | +2.6% | 1.1× |
| Q4 FY26 | 21 May 2026 | +5.0% | +14.3% | +15.1% | 4.4× |
| Q3 FY26 | 9 Feb 2026 | -1.4% | -0.2% | -4.2% | 20.9× |
| Q2 FY26 | 4 Nov 2025 | +0.3% | -1.8% | -7.0% | 0.2× |
| Q1 FY26 | 7 Aug 2025 | -3.4% | -1.5% | -5.8% | 0.6× |
| Q4 FY25 | 20 May 2025 | -1.1% | -0.9% | +19.6% | 1.7× |
| Q3 FY25 | 4 Feb 2025 | -2.9% | -12.1% | -18.7% | 0.3× |
| Q2 FY25 | 11 Nov 2024 | -1.2% | -6.5% | +22.7% | 4.9× |
| Q1 FY25 | 7 Aug 2024 | -2.1% | -7.4% | -1.8% | 0.1× |
| Q4 FY24 | 22 May 2024 | -3.2% | -6.0% | +6.2% | 3.7× |
| Q3 FY24 | 12 Feb 2024 | -2.2% | -0.7% | -9.1% | 0.5× |
| Q2 FY24 | 8 Nov 2023 | -0.9% | -3.7% | -6.1% | 1.3× |
| Q1 FY24 | 9 Aug 2023 | -3.5% | +9.6% | -9.7% | 1.3× |
| Q4 FY23 | 24 May 2023 | -3.6% | -1.9% | +10.4% | 0.9× |
| Q3 FY23 | 3 Feb 2023 | +1.3% | -2.3% | -28.1% | 7.4× |
| Q2 FY23 | 11 Nov 2022 | -0.4% | -4.3% | +0.5% | 0.1× |
| Q1 FY23 | 1 Aug 2022 | -4.3% | -6.8% | +4.3% | 0.6× |
| Q4 FY22 | 23 May 2022 | -7.5% | -5.5% | -17.0% | 2.6× |
| Q3 FY22 | 13 Feb 2022 | -4.6% | +8.0% | +5.2% | 1.1× |
| Q2 FY22 | 10 Nov 2021 | -1.5% | +1.3% | -3.9% | 0.5× |
| Q1 FY22 | 30 Jul 2021 | -0.9% | -1.4% | +21.0% | 1.7× |
| Q4 FY21 | 27 May 2021 | -1.5% | -1.9% | -7.2% | 0.7× |
| Q3 FY21 | 30 Jan 2021 | -5.9% | -6.8% | -5.7% | 1.0× |
| Q2 FY21 | 5 Nov 2020 | -2.3% | -0.3% | +22.5% | 0.5× |
| Q1 FY21 | 7 Aug 2020 | -2.2% | -5.0% | -9.5% | 0.8× |
| Q4 FY20 | 16 Jun 2020 | -3.9% | -2.8% | -11.3% | 0.3× |
| Q3 FY20 | 1 Feb 2020 | -1.8% | +1.6% | +6.6% | 0.9× |
| Q2 FY20 | 2 Nov 2019 | -6.1% | -7.7% | -6.2% | 1.5× |
| Q1 FY20 | 10 Aug 2019 | -3.9% | -5.8% | +5.4% | 1.6× |
| Q4 FY19 | 21 May 2019 | -0.9% | -1.5% | -13.8% | 0.5× |
| Q3 FY19 | 27 Feb 2019 | +1.9% | +5.7% | +31.5% | 1.0× |
| Q2 FY19 | 9 Nov 2018 | +4.0% | +5.5% | +12.9% | 2.1× |
| Q1 FY19 | 8 Aug 2018 | -0.7% | -0.9% | +1.8% | 0.2× |
| Q4 FY18 | 20 Jun 2018 | +2.3% | -8.4% | -9.4% | 0.1× |
| Q3 FY18 | 16 Mar 2018 | -4.1% | -7.2% | -2.8% | 0.5× |
| Q2 FY18 | 22 Nov 2017 | -3.4% | -0.9% | +1.0% | 0.7× |
| Q1 FY18 | 21 Aug 2017 | +2.9% | +3.5% | -2.4% | 0.1× |
| Q4 FY17 | 12 Jun 2017 | +4.6% | +20.4% | +1.3% | 4.2× |
| Q3 FY17 | 11 Feb 2017 | -2.4% | -0.6% | -3.9% | 0.4× |
| Q2 FY17 | 8 Dec 2016 | -3.2% | -11.3% | -9.7% | 0.0× |
| Q1 FY17 | 20 Sept 2016 | — | — | — | — |
| Q4 FY16 | 1 Jun 2016 | — | — | — | — |
| Q3 FY16 | 13 Feb 2016 | — | — | — | — |
| Q2 FY16 | 9 Nov 2015 | — | — | — | — |
| Q1 FY16 | 14 Aug 2015 | — | — | — | — |
| Q4 FY15 | 30 May 2015 | — | — | — | — |
| Q3 FY15 | 20 Feb 2015 | — | — | — | — |
| Q1 FY15 | 21 Aug 2014 | — | — | — | — |
| Q4 FY14 | 30 May 2014 | — | — | — | — |
| Q3 FY14 | 27 Feb 2014 | — | — | — | — |
| Q4 FY13 | 6 Jun 2013 | — | — | — | — |
| Q3 FY13 | 12 Feb 2013 | — | — | — | — |
| Q2 FY13 | 12 Nov 2012 | — | — | — | — |
| Q1 FY13 | 21 Aug 2012 | — | — | — | — |
| Q4 FY12 | 18 May 2012 | — | — | — | — |
| Q3 FY12 | 21 Feb 2012 | — | — | — | — |
| Q2 FY12 | 14 Nov 2011 | — | — | — | — |
| Q1 FY12 | 24 Aug 2011 | — | — | — | — |
| Q4 FY11 | 6 Jun 2011 | — | — | — | — |
| Q3 FY11 | 16 Feb 2011 | — | — | — | — |
| Q2 FY11 | 1 Nov 2010 | — | — | — | — |
| Q1 FY11 | 21 Jul 2010 | — | — | — | — |
| Q4 FY10 | 24 May 2010 | — | — | — | — |
| Q3 FY10 | 27 Jan 2010 | — | — | — | — |
| Q2 FY10 | 26 Oct 2009 | — | — | — | — |
| Q1 FY10 | 30 Jul 2009 | — | — | — | — |
| Q4 FY09 | 29 May 2009 | — | — | — | — |
| Q3 FY09 | 31 Jan 2009 | — | — | — | — |
| Q2 FY09 | 1 Nov 2008 | — | — | — | — |
| Q1 FY09 | 25 Jul 2008 | — | — | — | — |
| Q4 FY08 | 29 Apr 2008 | — | — | — | — |
| Q3 FY08 | 22 Jan 2008 | — | — | — | — |
| Q2 FY08 | 24 Oct 2007 | — | — | — | — |
| Q1 FY08 | 27 Jul 2007 | — | — | — | — |
| Q4 FY07 | 4 Jun 2007 | — | — | — | — |
| Average | -1.6% | -1.4% | -0.1% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+27.4%
Profit YoY—
Interest cost YoY+17.1%
Revenue QoQ+2.6%
Profit QoQ—
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | -30.8% | -21.5% | -20.0% | -8.4% | -7.5% | -5.8% |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen63.65
Day range57.20 – 63.65
52-week range38.33 – 76.85
From 52w high-23.4%
RSI (14)51.2
ATR (14)4.74
Volume81.0K
Avg volume (20D)58.8K
Rel volume1.38×
Volatility (1Y)52.6%
Turnover₹47.7L
SMA 50 / 20056.31 / 58.90
Delivery percentage
Latest · 6 Oct 202662.0%
20-day avg56.9%
1-year avg74.8%
Percentile (own history)34th
Range9.1–100.0%
Sessions1,728
Over the last 20 sessions KREBSBIO settled 56.9% of its traded quantity, which is above average for an NSE equity. Its one-year average is 74.8%, so recent sessions are running 17.9 points lower than usual. The latest session ranks higher than 34% of the 1,728 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -7.97% | +2.22% | +8.00% | +1.17% | +23.58% | -17.16% |
Valuation
CSVMarket cap₹127 Cr
P/E (TTM)—
EPS (TTM)-6.54
Shares outstanding2.16Cr
Listed3 Jan 1996
Ownership
CSVPromoter72.74%
Promoter Δ QoQ0.00 pp
Public27.26%
FII0.50%
DII0.00%
Pledged0.00%
Quarterly results · standalone
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 4.2 | 7.3 | 6.8 | 7.0 |
| YoY chg | -67.6% | -36.6% | +11.6% | +27.4% |
| Net profit (₹ Cr) | (6.1) | (3.1) | (2.3) | (2.5) |
| YoY chg | — | — | — | — |
| Net margin | -147.4% | -43.0% | -34.4% | -35.6% |
| EPS | -2.85 | -1.45 | -1.09 | -1.15 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 72.74% · public 27.26%2021-092026-06
- Promoter
- Public and others
- Promoter
- 72.74%
- Public
- 27.26%
- Promoter change
- 0.00 pp
- Filed
- 8 Jul 2026
- FII
- 0.50%
- DII
- 0.00%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSVStandalone
₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25A | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 14.9 | 13.0 | 12.0 | 12.9 | 12.9 | 11.5 | 6.1 | 5.5 | 4.2 | 7.3 | 6.8 | 7.0 | |
| Other income | 0.2 | 0.0 | 0.2 | 0.0 | 0.1 | 0.3 | 0.3 | 0.0 | 0.0 | 0.0 | 2.0 | 0.2 | |
| Total income | 15.1 | 13.0 | 12.2 | 12.9 | 12.9 | 11.7 | 6.4 | 5.5 | 4.2 | 7.3 | 8.8 | 7.1 | |
| Total expenses | 18.6 | 18.0 | 18.0 | 18.1 | 18.7 | 19.5 | 14.7 | 10.8 | 10.3 | 10.4 | 11.2 | 9.6 | |
| └ Finance costs | 1.1 | 1.2 | 1.3 | 1.3 | 1.4 | 1.6 | 1.6 | 1.7 | 1.7 | 1.8 | 1.9 | 1.9 | |
| └ Depreciation | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | |
| Profit before tax | (3.6) | (5.0) | (5.8) | (5.2) | (5.8) | (7.7) | (8.3) | (5.3) | (6.1) | (3.1) | (2.3) | (2.5) | |
| Tax expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net profit | (3.6) | (5.0) | (5.8) | (5.2) | (5.8) | (7.7) | (8.3) | (5.3) | (6.1) | (3.1) | (2.3) | (2.5) | |
| EPS | -1.66 | -2.31 | -2.72 | -2.40 | -2.67 | -3.59 | -3.83 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 | |
| Net margin | -23.98% | -38.35% | -48.84% | -40.12% | -44.81% | -67.49% | -135.54% | -97.14% | -147.40% | -42.98% | -34.36% | -35.58% | |
| PBT margin | -23.98% | -38.35% | -48.84% | -40.12% | -44.81% | -67.49% | -135.29% | -97.14% | -147.40% | -42.98% | -34.36% | -35.58% | |
| Tax rate | — | — | — | — | — | — | — | — | — | — | — | — |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 6 Aug 2026.
KREBSBIO at a glance
- KREBSBIO closed at ₹58.86 on 6 Oct 2026, -7.97% on the day, -17.2% over one year, 23.4% below its 52-week high of ₹76.85.
- Delivery was 62.0% of traded quantity on 6 Oct 2026, the 34th percentile of its own 1,728 sessions with a reading (20-session average 56.9%, 1-year average 74.8%).
- Market capitalisation is ₹127 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-6.54).
- Q1 FY27 results (standalone, filed 6 Aug 2026): revenue ₹7 crore (+27.4% year on year), net profit ₹-2 crore; the price moved +1.0% on the first session after.
- Promoters held 72.74% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 4 Nov 2026 and 11 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE268B01013
SeriesEQ
Listed3 Jan 1996
History from27 Oct 2016
Sessions2,406
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE